Cargando…

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial

IMPORTANCE: Deficient mismatch mutation repair mechanisms may sensitize endometrial cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an investigational anti–PD-1 antibody that binds with high affinity to the PD-1 receptor. OBJECTIVE: To assess the antitumor activity and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oaknin, Ana, Tinker, Anna V., Gilbert, Lucy, Samouëlian, Vanessa, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, Sabatier, Renaud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530821/ https://www.ncbi.nlm.nih.gov/pubmed/33001143 http://dx.doi.org/10.1001/jamaoncol.2020.4515

Ejemplares similares

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
por: André, Thierry, et al.
Publicado: (2023)

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
por: Kristeleit, Rebecca, et al.
Publicado: (2022)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
por: Patnaik, Amita, et al.
Publicado: (2021)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial
por: Ali, Eman, et al.
Publicado: (2022)

DNA damaging agents in ovarian cancer
por: Barretina-Ginesta, Maria-Pilar
Publicado: (2020)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer
por: Powell, Kerrington, et al.
Publicado: (2022)

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
por: Antill, Yoland, et al.
Publicado: (2021)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
por: Singh, Vanshikha, et al.
Publicado: (2022)

Dostarlimab, a boon or a healthcare burden- too early to acertain!
por: Fatima, Nabeela, et al.
Publicado: (2022)

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm
por: Goulden, Scott, et al.
Publicado: (2023)

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models
por: Kumar, Sujatha, et al.
Publicado: (2021)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

Rare ovarian tumours. Other treatments for ovarian cancer
por: Gil-Martin, Marta, et al.
Publicado: (2020)

Management of advanced ovarian cancer in Spain: an expert Delphi consensus
por: Redondo, Andres, et al.
Publicado: (2021)

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
por: Madariaga, Ainhoa, et al.
Publicado: (2023)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
por: Alkholifi, Faisal K., et al.
Publicado: (2022)

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
Publicado: (2022)

Interpreting Nonrandomized Evidence for Clinical Decision Making in Cardio-Oncology
por: Chatur, Safia, et al.
Publicado: (2023)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

SEOM-GEICO clinical guidelines on endometrial cancer (2021)
por: Barretina-Ginesta, María Pilar, et al.
Publicado: (2022)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

SEOM clinical guideline in ovarian cancer (2020)
por: Redondo, A., et al.
Publicado: (2021)

Effect of Lingual Frenotomy on Tongue and Lip Rest Position: A Nonrandomized Clinical Trial
por: Martinelli, Roberta Lopes Castro, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours
por: Melhem, Murad, et al.
Publicado: (2022)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
por: Jeong, Tae-Jun, et al.
Publicado: (2022)

Nonrandom network connectivity comes in pairs
por: Hoffmann, Felix Z., et al.
Publicado: (2017)

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2017)

Effects of chalazion and its treatments on the meibomian glands: a nonrandomized, prospective observation clinical study
por: Li, Junping, et al.
Publicado: (2020)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_trko0hdeu2sa0g1c5hc65dtisb